About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
PMID: 38075162 Journal: Advances in Laboratory Medicine Year: 2023 Reference: Adv Lab Med. 2023 Sep 8;4(3):205-206. doi: 10.1515/almed-2023-0113. eCollection 2023 Sep. Impact factor: Publication type: Editorial in national publication Authors: Arribas, Ignacio; Augustin, Salvador; Fernandez-Calle, Pilar; Ferrer-Costa, Roser; Ferrer-Costa, Roser; Gabriel-Medina, Pablo; Gonzalez, Alvaro; Guerrero, Rafael A; Jimenez, Wladimiro; Jimenez-Masip, Alba et al. DOI: 10.1515/almed-2023-0113
PMID: 38097770 Journal: Communications medicine Year: 2023 Reference: Commun Med (Lond). 2023 Dec 14;3(1):182. doi: 10.1038/s43856-023-00420-8. Impact factor: Publication type: Paper in international publication Authors: Araujo, Silvia G; Buti, Maria; Cardona, V; de la Hoz, B; Dieguez, M C; Fernandez, Emma; Forns, Xavier; Gonzalez-de-Olano, D; Habernau, A; Lazarus, Jeffrey V et al. DOI: 10.1038/s43856-023-00420-8
PMID: 38102226 Journal: BRITISH JOURNAL OF CANCER Year: 2023 Reference: Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02513-6. Impact factor: Publication type: Paper in international publication Authors: Aldecoa, Iban; Araujo, Silvia G; Buti, Maria; Castellano, Daniel; Climent, Miguel A; Fernandez, Emma; Fernandez, Pedro L; Font, Albert; Forns, Xavier; Gibson, Neil et al. DOI: 10.1038/s41416-023-02513-6
PMID: 38111084 Journal: LIVER INTERNATIONAL Year: 2023 Reference: Liver Int. 2023 Dec 18. doi: 10.1111/liv.15814. Impact factor: Publication type: Paper in international publication Authors: Barreira-Diaz, Ana; Buti, Maria; Esteban, Rafael; Feliu-Prius, Anna; Palom, Adriana; Rando, Ariadna; Riveiro-Barciela, Mar; Rodriguez-Frias, Francisco; Ruiz-Cobo, Juan C; Vargas-Accarino, Elena et al. DOI: 10.1111/liv.15814
PMID: 33526381 Journal: Hipertension y riesgo vascular Year: 2021 Reference: Hipertens Riesgo Vasc. 2021 Jul-Sep;38(3):125-132. doi: 10.1016/j.hipert.2020.12.001. Epub 2021 Jan 30. Impact factor: Publication type: Review in national publication Authors: Jacobs-Cacha, C; Molina-Van den Bosch, M; Seron, D; Soler, M J; Vergara, A et al. DOI: 10.1016/j.hipert.2020.12.001
PMID: 33338545 Journal: JOURNAL OF VIROLOGICAL METHODS Year: 2021 Reference: J Virol Methods. 2021 Mar;289:114039. doi: 10.1016/j.jviromet.2020.114039. Epub 2020 Dec 15. Impact factor: Publication type: Paper in international publication Authors: Alvarez-Lopez, Patricia; Barbosa, Gisela; Barreira-Diaz, Ana; Buti, Maria; Esteban, Rafael; Ferreira, Vicelma; Ferrer-Costa, Roser; Kuchta, Alison; Lopez, Eva; Martinez-Camprecios, Joan et al. DOI: 10.1016/j.jviromet.2020.114039
PMID: 33492457 Journal: PEDIATRIC NEPHROLOGY Year: 2021 Reference: Pediatr Nephrol. 2021 Apr;36(4):1025-1028. doi: 10.1007/s00467-020-04906-8. Epub 2021 Jan 25. Impact factor: Publication type: Paper in international publication Authors: Ariceta, Gema; Chocron, Sara; Ferrer, Roser; Giralt, Marina et al. DOI: 10.1007/s00467-020-04906-8
PMID: 33482272 Journal: JOURNAL OF CONTROLLED RELEASE Year: 2021 Reference: J Control Release. 2021 Mar 10;331:198-212. doi: 10.1016/j.jconrel.2021.01.022. Epub 2021 Jan 20. Impact factor: Publication type: Paper in international publication Authors: Abasolo, Ibane; Andrade, Fernanda; Arango, Diego; Boullosa, Ana; Camara-Sanchez, Patricia; Diaz-Riascos, Zamira V; Garcia-Aranda, Natalia; Martinez-Trucharte, Francesc; Montero, Sara; Nestor, Marika et al. DOI: 10.1016/j.jconrel.2021.01.022
Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.
Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.
Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.
